










 


    Daniel Getman | Kansas City Area Life Sciences Institute | ZoomInfo.com

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version















Insider Trading - Getman Daniel P - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Getman Daniel P





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-11-28Sale
2016-11-304:01 pm
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
20,000
$16.86
$337,268
63,799(Direct)
View


2015-08-28Sale
2015-08-314:57 pm
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
30,000
$28.14
$844,200
80,000(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-11-28Exercise
2016-11-304:01 pm
N/AN/A
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
16,201
$6.8
63,799(Direct)
View


2016-11-28Exercise
2016-11-304:01 pm
N/AN/A
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
3,799
$6.8
63,799(Direct)
View


2016-11-28Exercise
2016-11-304:01 pm
2015-05-092024-05-09
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
16,201
$6.8
63,799(Direct)
View


2016-11-28Exercise
2016-11-304:01 pm
2015-05-092024-05-09
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
3,799
$6.8
63,799(Direct)
View


2016-06-02Option Award
2016-06-066:01 pm
N/AN/A
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
9,800
$0
9,800(Direct)
View


2015-08-28Exercise
2015-08-314:57 pm
N/AN/A
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
30,000
$3.2
80,000(Direct)
View


2015-08-28Exercise
2015-08-314:57 pm
N/A2021-09-01
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
30,000
$3.2
80,000(Direct)
View


2015-05-29Option Award
2015-06-025:38 pm
N/A2025-05-29
Sucampo Pharmaceuticals Inc.
SCMP
Getman Daniel PDirector
20,000
$16.23
110,000(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 18:39:37 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











SCMP Daniel P. Getman Insider Trades for Sucampo Pharmaceuticals Inc. Cl A


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Sucampo Pharmaceuticals Inc. Cl A

                  NASDAQ: SCMP
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Sucampo Pharmaceuticals Inc. Cl A



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:29 p.m.


SCMP

/quotes/zigman/101695/composite


$
10.85




Change

0.00
0.00%

Volume
Volume 36,535
Quotes are delayed by 20 min








/quotes/zigman/101695/composite
Today's close

$
			10.80
		


$
				10.85
			
Change

+0.05
+0.46%





Day low
Day high
$10.65
$11.00










52 week low
52 week high

            $9.30
        

            $17.55
        


















Insider Activity


Individual




Daniel P. Getman



Dr. Daniel P. Getman is Member-Managers Board at Childrens Discovery Institute and Member-National Council at Washington University School of Medicine. He  is on the Board of Directors at Sucampo Pharmaceuticals, Inc. and Kansas Bioscience Organization. 
Dr. Getman was previously employed as Chairman by Missouri Biotechnology Association and President by Kansas City Area Life Sciences Institute, Inc. 
He received his undergraduate degree from State University of New York at Buffalo and a doctorate degree from the University of Minnesota.



Transactions


Date
Shares
Transaction
Value





11/29/2016
3,799


 
Disposition at $16.75 per share.


63,634


11/29/2016
3,799


 
Derivative/Non-derivative trans. at $6.8 per share.


25,833


11/28/2016
16,201


 
Disposition at $16.89 per share.


273,635


11/28/2016
16,201


 
Derivative/Non-derivative trans. at $6.8 per share.


110,166


06/02/2016
9,800


 
Award at $0 per share.


0


08/28/2015
30,000


 
Disposition at $28.14 per share.


844,200


08/28/2015
30,000


 
Derivative/Non-derivative trans. at $3.2 per share.


96,000





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Peter S. Greenleaf 
Chairman & Chief Executive Officer




Mr. Peter P. Pfreundschuh 
Chief Financial Officer




Mr. Matthew Maxwell Donley 
EVP-Human Resources & Information Technology




Dr. Peter Alec Kiener 
Chief Scientific Officer




Dr. Peter  Lichtlen 
Chief Medical Officer




Mr. Matthias A. Alder 
Executive Vice President




Dr. Jones Woody Bryan 
Senior Vice President-Business Development




Mr. Gregory A. Deener 
Senior VP-Marketing Strategy & Implementation




Dr. Karen L. Smith 
Director




Mr. Paul R. Edick 
Director




Mr. Timothy P. Walbert 
Director




Dr. Robert Jay Spiegel 
Director




Dr. Daniel P. Getman 
Director




Ms. Elissa  Cote 
SVP-Global Strategic Marketing




Ms. Silvia  Taylor 
SVP-Investor Relations & Corporate Communications




Mr. Alex  Driggs 
Secretary & General Counsel




Dr. Steven  Caffé 
Senior Vice President-Regulatory Affairs




Mr. John H. Johnson 
Lead Independent Director




Ms. Maureen E. O'Connell 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




7:39 PM EDT
July 28, 2017


/marketstate/country/us
New York

	After


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
7:29pA Wild Week in Washington 
6:50pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
6:08pHere’s one Trump fan who might make you some money
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Getman Daniel P Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      Getman Daniel P
                    

•   MISSION HILLS, KS
                      
How do I update this listing?




                                             Getman Daniel P is based out of Mission Hills.    WhaleWisdom has at least 3 insider transactions (Form 3,4,5) in our database for Getman Daniel P. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from Getman Daniel P, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




getman daniel p


6923 BELINDER AVE

MISSION HILLS
KS
                                                        
                                                    66208


                                                      Business Phone:
                                                      3019613400
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 11/30/2016
4 filed on 06/06/2016
4 filed on 08/31/2015
4 filed on 06/02/2015
4 filed on 06/09/2014
4 filed on 05/30/2013
4 filed on 06/05/2012
3 filed on 09/07/2011
4 filed on 09/07/2011
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free




















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft


















Daniel P. Getman Ph.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In




















Daniel P. Getman Ph.D.
Former Board Member at Sucampo Pharmaceuticals, Inc.


View Full Profile
Are you Daniel P. Getman Ph.D.? Claim your profile


 


Sign up for Equilar Atlas and view Daniel P. Getman Ph.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Daniel P. Getman Ph.D.'s  network and community.
												FOLLOW changes in Daniel P. Getman Ph.D.'s employment and money-in-motion.
												CONNECT with Daniel P. Getman Ph.D. through your network of contacts.
												








Daniel P. Getman Ph.D.'s Executive Work History


Past
To view Daniel P. Getman Ph.D.'s complete executive work history, sign up now
Education


														 Ph.D., 
															University of Minnesota 


														 B.S., 
															SUNY at Buffalo


Age
61

 
 






Sign up for Equilar Atlas and view Daniel P. Getman Ph.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Daniel P. Getman Ph.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Daniel P. Getman Ph.D.'s  network and community.
												FOLLOW changes in Daniel P. Getman Ph.D.'s employment and money-in-motion.
												CONNECT with Daniel P. Getman Ph.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Daniel P. Getman Ph.D.


















Daniel P. Getman Ph.D.'s Connections (53)





Sign up now to view Daniel P. Getman Ph.D.'s 53 connections »









Paul R. Edick
Board Member, NewLink Genetics Corporation









Stanley G. Miele
Chief Commercial Officer, Sucampo Pharmaceuticals, Inc.









Matthew M. Donley
Executive Vice President, Global Human Resources, Information Technology and Strategy, Sucampo Pharmaceuticals, Inc.









Sachiko Kuno
Former Founding CEO and Co-Founder, Sucampo Pharmaceuticals, Inc.









Peter Lichtlen
Chief Medical Officer, Sucampo Pharmaceuticals, Inc.









Thomas J. Knapp
Interim General Counsel and Corporate Secretary, Galena Biopharma, Inc.









Peter A. Kiener
Chief Science Officer, Sucampo Pharmaceuticals, Inc.









John H. Johnson
Board Member, Cempra, Inc.









William L. Ashton
Board Member, Galena Biopharma, Inc.









Robert J. Spiegel
Board Member, Geron Corporation








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993


















Daniel P. Getman is no longer serving in their board position at Sucampo Pharmaceuticals, Inc.


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology












See more news on Board and Executive Moves




        Daniel P. Getman is no longer serving in their board position at Sucampo Pharmaceuticals, Inc.    























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 

          Jun 9, 2017                         - RelSci Data Update                

          Board and Executive Moves      




Background Information:


Daniel P. Getman »
Member-Managers Board at Childrens Discovery Institute


Career:




                                                                Childrens Discovery Institute                                                            







                                                                Kansas City Area Life Sciences Institute, Inc.                                                            





Boards:




                                                                Sucampo Pharmaceuticals, Inc.                                                            







                                                                Kansas City Area Life Sciences Institute, Inc.                                                            







                                                                Washington University in St.Louis - School of Medicine                                                            





Education:




                                                                State University of New York - University at Buffalo                                                            







In The News:




                            Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors                            


                            December 15, 2015  •  GlobeNewswire                        





                            Arlington's Opower files confidential paperwork to go public                            


                            February 17, 2014  •  The Washington Post                        





                            Sucampo Names Peter Greenleaf Chief Executive Officer                            


                            February 10, 2014  •  Thomson Reuters ONE                        









Daniel P. Getman »
Member-Managers Board at Childrens Discovery Institute






Career:

•


                                                                                    Childrens Discovery Institute                                                                                    



•


                                                                                    Kansas City Area Life Sciences Institute, Inc.                                                                                    




Boards:

•


                                                                                    Sucampo Pharmaceuticals, Inc.                                                                                    



•


                                                                                    Kansas City Area Life Sciences Institute, Inc.                                                                                    



•


                                                                                    Washington University in St.Louis - School of Medicine                                                                                    




Education:

•


                                                                                    State University of New York - University at Buffalo                                                                                    







In The News:




 


                                                    Sucampo CEO Peter Greenleaf Appointed Chairman of the Board of Directors                                                





                                     December 15, 2015  •  GlobeNewswire                                





 


                                                    Arlington's Opower files confidential paperwork to go public                                                





                                     February 17, 2014  •  The Washington Post                                





 


                                                    Sucampo Names Peter Greenleaf Chief Executive Officer                                                





                                     February 10, 2014  •  Thomson Reuters ONE                                








Sucampo Pharmaceuticals, Inc. »
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.




In The News:




                            Sucampo Pharmaceuticals, Inc. filed form 10-Q                            


                            May 3, 2017  •  SEC                        





                            Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank nd Annual Health Care Conference                            


                            April 26, 2017  •  GlobeNewswire                        





                            Sucampo Announces First Quarter 2017 Earnings Call                            


                            April 19, 2017  •  GlobeNewswire                        









Sucampo Pharmaceuticals, Inc. »
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.






In The News:




 


                                                    Sucampo Pharmaceuticals, Inc. filed form 10-Q                                                





                                     May 3, 2017  •  SEC                                





 


                                                    Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank nd Annual Health Care Conference                                                





                                     April 26, 2017  •  GlobeNewswire                                





 


                                                    Sucampo Announces First Quarter 2017 Earnings Call                                                





                                     April 19, 2017  •  GlobeNewswire                                








See more news on Board and Executive Moves









You've found a premium RelSci Pro feature!



Connect to Individuals and Organizations In This Story

Upgrade to RelSci Pro to easily sync your contacts and see how you can reach the people and organizations featured in this article.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now










Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤













